Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for prevention of contrast-induced nephropathy after PCI
IRCT20220521054950N1Phase 3Completed
- Sponsor
- NIMAD
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of empagliflozin in contrast-induced nephropathy (CIN), sponsored by NIMAD. Started Jul 2022; status: completed.
02
Drugs
empagliflozin
03
Conditions
contrast-induced nephropathy (CIN)
Beyond the preview
Go deeper on IRCT20220521054950N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220521054950N1.